Cargando…

Emerging Potential Mechanism and Therapeutic Target of Ferroptosis in PDAC: A Promising Future

Pancreatic cancer (PC) is a devastating malignant tumor of gastrointestinal (GI) tumors characterized by late diagnosis, low treatment success and poor prognosis. The most common pathological type of PC is pancreatic ductal adenocarcinoma (PDAC), which accounts for approximately 95% of PC. PDAC is p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Chang, Yin, Xunzhe, Liu, Zuojia, Wang, Jin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9740869/ https://www.ncbi.nlm.nih.gov/pubmed/36499358 http://dx.doi.org/10.3390/ijms232315031

Ejemplares similares

Targeting KRAS in PDAC: A New Way to Cure It?
por: He, Qianyu, et al.
Publicado: (2022)

Non-Alcoholic Fatty Liver Disease (NAFLD) Pathogenesis and Natural Products for Prevention and Treatment
por: Guo, Xiangyu, et al.
Publicado: (2022)

Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease
por: Yin, Xunzhe, et al.
Publicado: (2023)

Emerging Potential Therapeutic Targets of Ferroptosis in Skeletal Diseases
por: Liu, Xin, et al.
Publicado: (2022)

The Microbiome in PDAC—Vantage Point for Future Therapies?
por: Pfisterer, Nina, et al.
Publicado: (2022)

The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC
por: Brown, Matthew, et al.
Publicado: (2020)

Targeting Ferroptosis as a Promising Therapeutic Strategy for Ischemia-Reperfusion Injury
por: Pan, Yihang, et al.
Publicado: (2022)

Discovery of Small Molecule NSC290956 as a Therapeutic Agent for KRas Mutant Non-Small-Cell Lung Cancer
por: Zhang, Jiaxin, et al.
Publicado: (2022)

A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein βig-h3
por: de la Fouchardière, Christelle, et al.
Publicado: (2022)

Complement and Fungal Dysbiosis as Prognostic Markers and Potential Targets in PDAC Treatment
por: Speth, Cornelia, et al.
Publicado: (2022)

Ferroptosis in osteosarcoma: A promising future
por: Liu, Xiang, et al.
Publicado: (2022)

Biological Hallmarks and New Therapeutic Approaches for the Treatment of PDAC
por: Digiacomo, Graziana, et al.
Publicado: (2021)

Ferroptosis: A Promising Therapeutic Target for Neonatal Hypoxic-Ischemic Brain Injury
por: Peeples, Eric S., et al.
Publicado: (2022)

Ferroptosis in inflammatory arthritis: A promising future
por: Chang, Siyuan, et al.
Publicado: (2022)

Targeting ferroptosis in renal cell carcinoma: Potential mechanisms and novel therapeutics
por: Yang, Lei, et al.
Publicado: (2023)

Molecular mechanisms of ferroptosis and the potential therapeutic targets of ferroptosis signaling pathways for glioblastoma
por: Zhang, Meng, et al.
Publicado: (2022)

Implication of Ferroptosis in Cholangiocarcinoma: A Potential Future Target?
por: Yang, Mingyu, et al.
Publicado: (2023)

Mechanisms of ferroptosis and targeted therapeutic approaches in lymphoma
por: Yu, Tiantian, et al.
Publicado: (2023)

Targeting ferroptosis as a promising therapeutic strategy to treat cardiomyopathy
por: Sun, Huiyan, et al.
Publicado: (2023)

Emerging significance and therapeutic targets of ferroptosis: a potential avenue for human kidney diseases
por: Li, Jinghan, et al.
Publicado: (2023)

Ferroptosis Modulation: Potential Therapeutic Target for Glioblastoma Treatment
por: de Souza, Izadora, et al.
Publicado: (2022)

The promising potential of piperlongumine as an emerging therapeutics for cancer
por: Parama, Dey, et al.
Publicado: (2021)

A Promising Future of Ferroptosis in Tumor Therapy
por: Wang, Hui, et al.
Publicado: (2021)

Fendiline Enhances the Cytotoxic Effects of Therapeutic Agents on PDAC Cells by Inhibiting Tumor-Promoting Signaling Events: A Potential Strategy to Combat PDAC
por: Alhothali, Marwa, et al.
Publicado: (2019)

Emerging Role of Ferroptosis in Diabetic Kidney Disease: Molecular Mechanisms and Therapeutic Opportunities
por: Wang, Hui, et al.
Publicado: (2023)

Ferroptosis as an emerging therapeutic target in liver diseases
por: Lu, Yuzhen, et al.
Publicado: (2023)

Ferroptosis in pulmonary fibrosis: an emerging therapeutic target
por: Wang, Chunyan, et al.
Publicado: (2023)

Ferroptosis: A Potential Therapeutic Target in Acute Kidney Injury
por: Hosohata, Keiko, et al.
Publicado: (2022)

Ferroptosis: A potential therapeutic target in autoimmune disease (Review)
por: Shen, Liang, et al.
Publicado: (2023)

Harnessing Ferroptosis to Overcome Drug Resistance in Colorectal Cancer: Promising Therapeutic Approaches
por: Cheng, Xiaofei, et al.
Publicado: (2023)

TIMP-1 and CD82, a promising combined evaluation marker for PDAC
por: Zhang, Jiexin, et al.
Publicado: (2016)

Ferroptosis: A New Promising Target for Lung Cancer Therapy
por: Xiong, Rui, et al.
Publicado: (2021)

Ferroptosis as a promising therapeutic strategy for melanoma
por: Ta, Na, et al.
Publicado: (2023)

Ferroptosis: A New Promising Target for Ovarian Cancer Therapy
por: Zhao, Hongjiang, et al.
Publicado: (2022)

Mitochondrial Metabolism in PDAC: From Better Knowledge to New Targeting Strategies
por: Reyes-Castellanos, Gabriela, et al.
Publicado: (2020)

Ferroptosis: An emerging therapeutic opportunity for cancer
por: Wang, Liyuan, et al.
Publicado: (2020)

The Road from AKI to CKD: Molecular Mechanisms and Therapeutic Targets of Ferroptosis
por: Guo, Runzhi, et al.
Publicado: (2023)

Ferroptosis and renal fibrosis: A new target for the future (Review)
por: Zhang, Han Yin, et al.
Publicado: (2022)

Emerging Role of Ferroptosis in the Pathogenesis of Ischemic Stroke: A New Therapeutic Target?
por: Bu, Zhong-Qi, et al.
Publicado: (2021)

Potential intervention target of atherosclerosis: Ferroptosis
por: Li, Jia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_67qnmjrvf1np1tc7ggjk2d01ic